Veran Medical Technologies, Inc., a lung cancer diagnostic company that enables physicians to diagnose early-stage lung cancer, received a $20M investment from BTG, a global healthcare company focused on Interventional Medicine.
“We are excited to announce BTG’s investment in Veran and look forward to collaborating with them,” said Veran Medical CEO Jason Pesterfield. “BTG and Veran have the shared goal of helping physicians diagnose and treat lung cancer earlier in order to save lives.”
Veran’s SPiN Thoracic Navigation System™ is a revolutionary technology that helps speed time to diagnosis and provides pinpoint thoracic guidance for lifesaving therapies for lung cancer patients. The SPiN System™ provides best in class cancer treatment providers with a scalable platform solution that can also be utilized for managing other leading cancers like liver and kidney cancers.
“We are pleased to enter into this partnership with Veran and support the company’s growth,” said Peter Pattison, BTG’s Head of Interventional Oncology. “Veran’s technology supports the shift towards minimally invasive treatment of lung cancer, an area of strategic interest to BTG.”